JMP keeps Anadys at market perform

Anadys Pharmaceuticals, Inc. was reiterated at market outperform by JMP Securities analyst Adam Cutler after JMP said the company is trading near cash but is still in watch-and-wait mode. Anadys reported third-quarter earnings per share of negative $0.22 versus estimates of negative $0.18 and the consensus estimate of negative $0.23. Shares of the San Diego-based biopharmaceutical company were up 5 cents, or 1.41%, at $3.60, on volume of 515,782 shares versus the three-month running average of 281,076 shares. (Nasdaq: ANDS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.